IMATINIB TEVA 400 mg, film-coated tablet 30 tablets, parallel import (BB Farma)
Active ingredients: Imatinib, Imatinib mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tablets, parallel import (BB Farma)orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IMATINIB TEVA 400 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) thermoformée(s) PVC polyéthylène PVDC aluminium de 1 comprimé(s) (distributeur parallèle : BB Farma)
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 4 Mar 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64706096CIP74950093CIP133400949500932Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IMATINIBcomprimé | 400 mg · un comprimé | FT |
| MÉSILATE D'IMATINIBcomprimé | 477,877 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.